Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TOP2A | P11388 | 3/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604336 | 0.80 | ALDH1A1 (0.41) | KMT2AMAPTGAATOP2ATOP2B | |
| SCHEMBL669754 | 0.74 | MAPT (0.33) | KMT2AMAPTGAAKDM4ERXFP1 | |
| SCHEMBL457599 | 0.72 | TYMS (0.37) | KMT2AMAPTKDM4ECYP1A2ALDH1A1 | |
| SCHEMBL28718347 | 0.70 | RAB9A (0.40) | KMT2AMAPTGAATOP2ATOP2B | |
| Anthracene SCHEMBL28233789 | 0.70 | CES1 (0.39) | KMT2AMAPTGAAKDM4ECYP1A2 | |
| SCHEMBL261907 | 0.70 | CES1 (0.39) | KMT2AMAPTGAAKDM4ECYP1A2 | |
| SCHEMBL8791995 | 0.67 | CES1 (0.54) | KMT2AMAPTKDM4ECYP1A2ALDH1A1 | |
| SCHEMBL670495 | 0.67 | KDM4E (0.59) | KMT2AMAPTGAATOP2AKDM4E | |
| SCHEMBL4674985 | 0.66 | NPC1 (0.41) | KMT2AMAPTGAAKDM4ERXFP1 | |
| SCHEMBL1875572 | 0.66 | RAB9A (0.41) | KMT2AMAPTGAATOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | SHENZHEN XUHUA BIOTECH CO. LTD. (CN) | 2023-07-13 | — | — | US | claimed |
| EP-3826717-A2 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND/OR TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2021-06-02 | — | — | EP | claimed |
| WO-2020023700-A2 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (Tdp1) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-01-30 | — | — | WO | claimed |
| CN-114555189-B | Zanthoxylum nitidum base derivatives as inhibitors of topoisomerase IB (TOP 1) and/or tyrosyl-DNA phosphodiesterase 1 (TDP 1) | 美国政府健康及人类服务部 | 2024-08-02 | — | — | CN | disclosed |
| US-20240245795-A1 | PREPARATION METHOD AND APPLICATION OF ANTIBODY DRUG CONJUGATE | HYSLINK THERAPEUTICS (CN) | 2024-07-25 | — | — | US | disclosed |
| US-20240245799-A1 | PREPARATION METHOD FOR ANTIBODY-DRUG CONJUGATE, AND APPLICATION | HYSLINK THERAPEUTICS (CN) | 2024-07-25 | — | — | US | disclosed |
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | HYSLINK THERAPEUTICS (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4331612-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | Hyslink Therapeutics (CN) | 2024-03-06 | — | — | EP | disclosed |
| EP-4331613-A1 | PREPARATION METHOD FOR ANTIBODY-DRUG CONJUGATE, AND APPLICATION | Hyslink Therapeutics (CN) | 2024-03-06 | — | — | EP | disclosed |
| EP-4331611-A1 | PREPARATION METHOD AND APPLICATION OF ANTIBODY DRUG CONJUGATE | Hyslink Therapeutics (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | SHENZHEN XUHUA BIOTECH CO. LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| CN-114555189-A | Xanthophyllone derivatives as inhibitors of topoisomerase IB (TOP1) and/or tyrosyl-DNA phosphodiesterase 1(TDP1) | 美国政府健康及人类服务部 | 2022-05-27 | — | — | CN | disclosed |
| EP-3826717-A2 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND/OR TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020023700-A2 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (Tdp1) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-01-30 | — | — | WO | disclosed |
| US-9073920-B2 | Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor | PURDUE RESEARCH FOUNDATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130143878-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | PURDUE RESEARCH FOUNDATION (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012024437-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | PURDUE RESEARCH FOUNDATION (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143878-A1 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR | KRAS, QDPR, BTD | KMT2A 3863/4885MAPT 2790/4885GAA 509/4885 |
| US-20240245795-A1 | PREPARATION METHOD AND APPLICATION OF ANTIBODY DRUG CONJUGATE | MTX1, SI, MET | KMT2A 2955/4885MAPT 6/4885GAA 1671/4885 |
| US-20240245799-A1 | PREPARATION METHOD FOR ANTIBODY-DRUG CONJUGATE, AND APPLICATION | MTX1, MET, SI | KMT2A 2887/4885MAPT 7/4885GAA 1982/4885 |
| US-20240238440-A1 | PREPARATION METHOD FOR AND APPLICATION OF ANTIBODY CONJUGATED DRUG | SI, MET, MTX1 | KMT2A 3572/4885MAPT 9/4885GAA 2133/4885 |
| US-20230219895-A1 | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) | TDP1, TOP1, TOP2A | KMT2A 2665/4885MAPT 3230/4885GAA 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.